The iBio Technology has been validated by major industry players, as well as the Brazilian government, opening iBio’s doorway to the world market.
With extensive patent protection and proprietary know-how, iBio creates a high barrier to entry for competitors.
iBio’s global commercialization program, which was started in the favorable Brazilian market, is also licening the iBio Technology to key U.S. companies.
The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins and has been validated across a wide range of applications in both vaccines and biotherapeutics.

Company Growth (employees)
Type
Public
HQ
Newark, US
Founded
2008
Size (employees)
7 (est)
iBio was founded in 2008 and is headquartered in Newark, US

iBio Office Locations

iBio has an office in Newark
Newark, US (HQ)
100 9 Innovation Way

iBio Financials and Metrics

iBio Financials

iBio's revenue was reported to be $948 k in FY, 2016
USD

Revenue (Q3, 2017)

37 k

EBIT (Q3, 2017)

(3.9 m)

Market capitalization (13-Nov-2017)

25.8 m

Cash (31-Mar-2017)

12.4 m
iBio's current market capitalization is $25.8 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

205 k1.9 m948 k

Revenue growth, %

803%(49%)

R&D expense

1.9 m3.5 m3.2 m

General and administrative expense

3.9 m5 m7.7 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

819 k349 k160 k134 k379 k135 k75 k37 k

R&D expense

552 k585 k343 k1.2 m815 k551 k704 k1 m

General and administrative expense

949 k1.1 m951 k1.1 m1.2 m1.4 m1.7 m2.4 m2.5 m2.4 m2.8 m

Operating expense total

(240 k)1.6 m1.3 m2.2 m2 m2 m2.4 m3.5 m3.3 m3.4 m4 m
USDFY, 2014FY, 2015FY, 2016

Cash

3.6 m9.5 m23 m

Inventories

118 k182 k264 k

Current Assets

3.9 m10.1 m23.9 m

PP&E

6 k13 k25.6 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

3.4 m5.7 m4.3 m3.5 m8.1 m8.4 m6.7 m21.9 m20.1 m16.3 m12.4 m

Current Assets

4.6 m6.9 m5.5 m4.1 m9 m9.1 m7.2 m22.7 m20.5 m16.7 m13 m

PP&E

5 k7 k20 k14 k10 k14 k25.8 m25.6 m25.5 m25.8 m

Total Assets

7.3 m9.6 m8.2 m6.7 m11.4 m11.4 m9.4 m50.7 m48.1 m44.2 m40.7 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(3.7 m)(6.6 m)(10.7 m)

Depreciation and Amortization

361 k363 k940 k

Inventories

97 k(64 k)(82 k)

Accounts Payable

56 k806 k(125 k)
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

379 k(1.6 m)(1.3 m)(1.4 m)(1.7 m)(1.8 m)(4.1 m)(3.6 m)

Depreciation and Amortization

92 k184 k537 k412 k826 k1.3 m

Accounts Payable

1.1 m516 k815 k171 k190 k342 k53 k(255 k)7 k

Cash From Operating Activities

(1.1 m)(2.8 m)(5.3 m)(2.3 m)(5.8 m)(9.4 m)
USDY, 2017

Revenue/Employee

5.3 k

Financial Leverage

3.1 x
Show all financial metrics

iBio Operating Metrics

FY, 2016

Patents Issued

67

Patents Pending

19
Show all operating metrics

iBio Market Value History

iBio Revenue Breakdown

iBio's Web-traffic and Trends

iBio Company Life and Culture

You may also be interested in